RGLS Insider Equity Canceled for Cash & CVRs After Novartis Deal
Rhea-AI Filing Summary
Regulus Therapeutics Inc. (RGLS) – Form 4 insider transaction report
Chief Financial Officer Crispina Calsada disclosed the disposition of all 140,228 directly-held common shares and the cancellation of 1,628,500 stock options as of 25 June 2025. The transactions were executed automatically under the April 29 2025 Agreement and Plan of Merger among Regulus, Redwood Merger Sub Inc. and Novartis AG.
• At the merger’s effective time, each Regulus share was converted into the right to receive $7.00 cash plus one contingent value right (CVR).
• In-the-money options (exercise price < $7.00) were converted into cash equal to ($7.00 – strike price) × number of shares plus one CVR per underlying share.
• Out-of-the-money options (strike ≥ $7.00 < $14.00) were canceled for CVRs only, which may pay cash if a defined milestone is achieved.
Following these conversions, the reporting person reports zero remaining direct or indirect ownership in Regulus equity securities. The filing finalises insider equity treatment resulting from the completion of Novartis’ tender offer and subsequent merger, after which Regulus became a wholly owned subsidiary of Novartis.
Positive
- Shareholders receive $7.00 cash per share plus one CVR, providing immediate liquidity and potential future upside.
- In-the-money options converted to cash, indicating insiders realise value rather than options expiring unexercised.
Negative
- All public equity canceled, ending Regulus’ status as an independent publicly traded entity.
- Out-of-the-money options only receive CVRs, offering uncertain future value dependent on milestone achievement.
Insights
TL;DR – Insider equity fully cashed-out or swapped for CVRs under completed $7.00-per-share Novartis takeover.
The Form 4 confirms mechanical settlement of insider equity at closing. All common shares and 1.63 million options held by the CFO were canceled in exchange for cash and/or CVRs according to the merger agreement. No elective sales occurred; treatment was mandatory for all holders. Investors gain clarity on insider compensation structure and on the final equity count, signalling that Regulus’ public float has effectively been eliminated. The CVR structure ties potential future payments to milestone achievement, keeping a residual upside for former shareholders. The disclosure is primarily confirmatory and carries limited incremental valuation impact beyond what was already embedded in merger terms.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option | 10,000 | $0.00 | -- |
| Disposition | Stock Option | 21,000 | $0.00 | -- |
| Disposition | Stock Option | 15,000 | $0.00 | -- |
| Disposition | Stock Option | 48,000 | $0.00 | -- |
| Disposition | Stock Option | 5,000 | $0.00 | -- |
| Disposition | Stock Option | 45,000 | $0.00 | -- |
| Disposition | Stock Option | 375,000 | $0.00 | -- |
| Disposition | Stock Option | 85,000 | $0.00 | -- |
| Disposition | Stock Option | 462,000 | $0.00 | -- |
| Disposition | Stock Option | 562,500 | $0.00 | -- |
| Disposition | Common Stock | 140,228 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, (i) each Share was converted into the right to receive the Offer Price and (ii) each performance stock unit ("PSU") was canceled and converted into the right to receive (A) an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of Shares underlying such PSU immediately prior to the Effective Time by (y) the Closing Amount plus (B) one CVR with respect to each such Share subject to such PSU immediately prior to the Effective Time. The 83,500 PSUs reported herein were unintentionally omitted from previous Form 4 filings made by the Reporting Person following the achievement of the performance-based vesting conditions applicable thereto. Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time. Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).
